Werewolf Therapeutics (HOWL) Other Non-Current Assets (2020 - 2025)
Werewolf Therapeutics (HOWL) posted quarterly Other Non-Current Assets of $901000.0 for Q4 2025, down 26.15% year-over-year from $1.2 million in Q4 2024, and little changed on a QoQ basis from $898000.0 in Q3 2025.
Werewolf Therapeutics (HOWL) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Werewolf Therapeutics has reported Other Non-Current Assets for 6 years, with the latest figure at $901000.0 in Q4 2025.
- Other Non-Current Assets for Q4 2025 came in at $901000.0, down 26.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $901000.0 (down 26.15% YoY), and the FY2025 annual result was $901000.0, down 26.15% from the prior year.
- Other Non-Current Assets steadied at $901000.0 in Q4 2025, from $898000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $21.2 million in Q1 2023 and troughed at $300000.0 in Q1 2021.
- A 5-year average of $6.1 million and a median of $1.2 million in 2022 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2023, when Other Non-Current Assets soared 1654.97%; it then plunged 95.76% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.2 million in 2021, then climbed by 14.24% to $1.4 million in 2022, then soared by 1423.41% to $21.0 million in 2023, then slumped by 94.2% to $1.2 million in 2024, then declined by 26.15% to $901000.0 in 2025.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $901000.0 in Q4 2025, $898000.0 in Q3 2025, and $895000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 898,000.00 |
| Jun 30, 2025 | 122,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 320,000.00 |
| Sep 30, 2024 | 42,000.00 |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 21.02 Mn |
| Sep 30, 2023 | 21.02 Mn |
| Jun 30, 2023 | 652,000.00 |
| Mar 31, 2023 | 21.20 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.21 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.21 Mn |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 298,000.00 |